AHR agonist 10
AHR agonist 10 is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research.
For research use only. We do not sell to patients.
- CAS No.: 1191937-43-5
- Formula: C18H20O3
- Molecular Weight:284.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-6 |
IL-8 |
AHR agonist 10 (Compound B19) (10 μM, 20 μM, 24 h) can effectively enhance the expression levels of CYP1A1 and CYP1B1 in the AHR knockdown HaCaT cells[1].
AHR agonist 10 (5 μM) can suppress the expression on the mRNA level of CYP1A1, CYP1B1, CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1 on the Lipopolysaccharides (HY-D1056) (LPS)-induced HaCaT cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AHR knockdown HaCaT cell
-
Concentration:10 μM , 20 μM
-
Incubation Time:24 h
-
Result:Enhanced the expression levels of CYP1A1 and CYP1B1 on the HaCaT cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Babl/C mice (7-8 weeks old) were administered topically with Imiquimod (62.5 mg/mouse) on the hair-free back[1].
-
Dosage:1%
-
Administration:Topical application, once daily, 7 days
-
Result:Exhibited the ability to decrease the thickness of the stratum corneum and stratum spinosum of the skin , ameliorating epidermal hyperplasia.
Downregulated the expression of Ki67 and PCNA.
Mitigated psoriasis-associated epidermal hyperplasia by curbing excessive epidermal cell proliferation.
Enhanced the expression levels of ZO-1 and occludin.
Downregulated the expression levels of IL-17, IL-23, and IL-17F, effectively halting the progression of psoriasis by disrupting the responsible cytokine cascade and subsequent inflammatory response.
Effectively activated the AHR pathway, leading to enhanced expression levels of CYP1A1, CYP1B1, and HSP90.
Chemical Information
-
CAS No. 1191937-43-5
-
Molecular Weight 284.35
-
Formula C18H20O3
-
SMILES
CC(C1=C(C=C(C=C1O)/C=C/C2=CC=C(C=C2)OC)O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AHR agonist 10 Related Classifications
HY-178053 Related Classifications
Powered by Bioz